NCT04998981已完成3 期
A Phase 3, Multi-Center, Placebo- and Active-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 353
- 试验地点
- 33
- 主要终点
- Percent change in fasting TG versus placebo from baseline to Weeks 8 and 12
研究概览
简要总结
A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients with High TG and Low HDL-C
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects are eligible to be included in the study only if all of the following criteria apply:
- •Ability to understand and comply with study procedures and give written informed consent
- •Following the diet and lifestyle recommendations at least 12 weeks prior to the treatment period
- •Males or post-menopausal females
- •Aged ≥18 years at the time of informed consent
- •Fasting serum TG levels ≥200 mg/dL (≥2.26 mmol/L) and ≤500 mg/dL (5.65 mmol/L) at screening
- •Serum HDL-C <50 mg/dL (<1.30 mmol/L) if male or <55 mg/dL (<1.42 mmol/L) if female at screening.
排除标准
- •Subjects are excluded from the study if any of the following criteria apply:
- •Current or planned use of any lipid-altering medications other than the study drugs, statins, or ezetimibe during the study.
- •i. Subjects currently on statins or ezetimibe must be at high risk for atherosclerotic CV diseases, and the dose(s) must be stable for at least 4 weeks prior to screening
- •ii. For subjects currently on lipid-altering medications other than statins or ezetimibe, at least 4-week washout period (or for subjects currently on probucol at least 8 week washout period) will be required prior to the first fasting blood sampling at Screening Visit
- •Type 1 diabetes mellitus or poorly controlled Type 2 diabetes mellitus defined by HbA1c (NGSP level) ≥8.0% at screening
- •Uncontrolled hypertension defined by seated systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at screening
- •Uncontrolled thyroid disorder
- •Creatinine ≥1.5 mg/dL at screening
- •Severe hepatic disorder defined as cirrhosis of Child-Pugh class B or C, or AST or ALT >2 × ULN at screening
- •History of pancreatitis
- •Gallbladder disorder, history of cholelithiasis, primary biliary cirrhosis, or history of disease or surgery that may affect the absorption, distribution, metabolism and excretion of drugs or the metabolism of bile salts
- •Unexplained creatine kinase (CK) >5 × ULN at screening
- •Myocardial infraction or stroke (including transient ischemic attack) within 3 months prior to the informed consent
- •New York Heart Association Class III or IV heart failure
- •History of malignancy within 5 years
- •Participation in another clinical study at the time of informed consent or administration of an investigational drug other than placebo within 16 weeks prior to the informed consent for this study
研究组 & 干预措施
K-877 0.1 mg BID
Experimental
K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily
干预措施: Placebo capsule (Drug)
K-877 0.1 mg BID
Experimental
K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily
干预措施: K-877 0.1 mg tablet (Drug)
K-877 0.1 mg BID
Experimental
K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily
干预措施: Placebo tablet (Drug)
K-877 0.2 mg BID
Experimental
K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily
干预措施: K-877 0.1 mg tablet (Drug)
K-877 0.2 mg BID
Experimental
K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily
干预措施: Placebo capsule (Drug)
Fenofibrate 200 mg QD
Active Comparator
Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily
干预措施: Fenofibrate 200 mg capsule (Drug)
Fenofibrate 200 mg QD
Active Comparator
Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily
干预措施: Placebo tablet (Drug)
Placebo
Placebo Comparator
Placcebo tablet x 2 twice daily, Placebo capsule once daily
干预措施: Placebo tablet (Drug)
Placebo
Placebo Comparator
Placcebo tablet x 2 twice daily, Placebo capsule once daily
干预措施: Placebo capsule (Drug)
结局指标
主要结局
Percent change in fasting TG versus placebo from baseline to Weeks 8 and 12
时间窗: From baseline to Weeks 8 and 12
Percent change in fasting TG versus fenofibrate from baseline to Weeks 8 and 12
时间窗: From baseline to Weeks 8 and 12
次要结局
- Percent change from baseline to the end of the treatment period in Apo A1 and Apo B(From baseline to Week 12)
- Percent change from baseline to the end of the treatment period in TG/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, LDL-C/HDL-C, LDL-C/Apo B, and Apo B/Apo A1(From baseline to Week 12)
- The incidence of adverse events and adverse drug reactions after the administration of the study drug(Up to Week 12)
- Change from baseline to Week 4, 8, and 12 in clinical laboratory tests (chemistry, hematology), vital signs (BP [mmHg], PR [bpm], weight [kg], waist [cm], and BMI [kg/m^2]; each parameter is evaluated individually.), 12-lead ECGs(From baseline to Week 4, 8, and 12)
- Percentage of patients who have achieved fasting TG <150 mg/dL at the end of the treatment period(At Week 12)
- Percent change from baseline to Weeks 8 and 12 in TC, LDL-C (direct method), LDL-C (Friedewald method), LDL-C (Martin/Hopkins equation), HDL-C (direct method), non-HDL-C (calculated), and remnant cholesterol (calculated)(From baseline to Weeks 8 and 12)
- Change from baseline to Weeks 8 and 12 in fasting TG, TC, LDL-C (direct method), LDL-C (Friedewald method), LDL-C (Martin/Hopkins equation), HDL-C (direct method), non-HDL-C (calculated), and remnant cholesterol (calculated)(From baseline to Weeks 8 and 12)
- Number and percentage of patients who experience laboratory abnormalities of special interest including, but not limited to ALT, AST, ALP, CK, and, creatinine during the treatment period(Up to Week 12)
研究者
研究点 (33)
Loading locations...
相似试验
已完成
2 期
HSK7653 in Chinese Patients with Impaired Glucose ToleranceImpaired Glucose ToleranceNCT04727580Haisco Pharmaceutical Group Co., Ltd.99
已完成
3 期
Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing SpondylitisAnkylosing SpondylitisNCT01248793Centocor, Inc.213
已完成
3 期
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate TherapyRheumatoid ArthritisNCT01248780Centocor, Inc.264
撤回
3 期
Phase 3 Study - Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)Skin Structures and Soft Tissue InfectionsNCT00876850Paratek Pharmaceuticals Inc
终止
3 期
Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)Skin Diseases, InfectiousNCT00865280Paratek Pharmaceuticals Inc143